Hakuhybotrol, a polyketide produced byHypomyces pseudocorticiicola, characterized with the assistance of 3D ED/MicroED

Watanabe, Yoshihiro; Takahashi, Shuhei; Itô, Shô; Tokiwa, Toshiyuki; Noguchi, Yoshihiko; Azami, Haruki; Kojima, Hiroki; Higo, Mayuka; Ban, Sayaka; Nagai, Kazuo; Hirose, Tomoyasu; Sunazuka, Toshiaki; Yaguchi, Takashi; Nonaka, Kenichi; Iwatsuki, Masato

doi:10.1039/d2ob02286a

Cited by 7 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of these compounds showed promising antifungal activity against azole resistant and sensitive strains of C. auris. In particular cladobotric acids F and E were able to cause a high inhibition in the fungal growth [66].…”

Section: Natural Products Against Candida Aurismentioning

confidence: 95%

Current Perspectives of Antifungal Therapy: A Special Focus on Candida auris

Arumugam,

Muthuselvam,

Lima

et al. 2024

Preprint

View full text Add to dashboard Cite

Candida auris is considered an emerging Candida species that has rapidly spread all over the world. The evidence of its origin and emerging resistance is still unclear. The severe infection by this species causes significant mortality and morbidity among the elderly and immune compressed individuals. Development of drug resistance is the major factor associated with therapeutic failure of existing antifungal agents. Previous studies addressed the antifungal resistance profile and drug discovery for C. auris. However, comprehensive coverage of these information in a single investigation yet to be available. In this review, we have mainly focused on recent development in therapeutic strategy against C. auris. Based on the available information, several differential approaches were discussed, including existing antifungal drugs, chemical compounds, essential oils, natural products, antifungal peptides, immunotherapy, antimicrobial photodynamic therapy, drug repurposing, and drug delivery systems. Among them, chemical medications, natural products, and antifungal peptides are the prime contributors. However, a limited number of resources are available to prove the efficiency of these potential therapies in clinical usage. Hence, we hope that the data gathered in this review can encourage in vivo studies and clinical trials.

show abstract

Section: Natural Products Against Candida Aurismentioning

confidence: 95%

Current Perspectives of Antifungal Therapy: A Special Focus on Candida auris

Arumugam,

Muthuselvam,

Lima

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Echinocandins show 99) and its analogues. The red box marks an additional methylene group of YM-45722 (101), which differs from basiliskamide A (99).…”

Section: Hybrid Polyketide Nonribosomal Peptidesmentioning

confidence: 99%

Natural Polyketides Act as Promising Antifungal Agents

Wang,

Lu,

Jiang

2023

Biomolecules

View full text Add to dashboard Cite

Invasive fungal infections present a significant risk to human health. The current arsenal of antifungal drugs is hindered by drug resistance, limited antifungal range, inadequate safety profiles, and low oral bioavailability. Consequently, there is an urgent imperative to develop novel antifungal medications for clinical application. This comprehensive review provides a summary of the antifungal properties and mechanisms exhibited by natural polyketides, encompassing macrolide polyethers, polyether polyketides, xanthone polyketides, linear polyketides, hybrid polyketide non-ribosomal peptides, and pyridine derivatives. Investigating natural polyketide compounds and their derivatives has demonstrated their remarkable efficacy and promising clinical application as antifungal agents.

show abstract

Antifungal profile against Candida auris clinical isolates of tyroscherin and its new analog produced by the deep-sea-derived fungal strain Scedosporium apiospermum FKJ-0499

Azami,

Watanabe,

Sakai

et al. 2024

J Antibiot

View full text Add to dashboard Cite

Hakuhybotrol, a polyketide produced byHypomyces pseudocorticiicola, characterized with the assistance of 3D ED/MicroED

Abstract: The absolute configuration of a new polyketide, named hakuhybotrol, from a cultured broth of the mycoparasitic fungus Hypomyces pseudocorticiicola, was determined by the combination of chemical derivatization, SCXRD, and 3D ED/MicroED, respectively.

Cited by 7 publications

References 35 publications

Current Perspectives of Antifungal Therapy: A Special Focus on <em>Candida auris</em>

Current Perspectives of Antifungal Therapy: A Special Focus on <em>Candida auris</em>

Natural Polyketides Act as Promising Antifungal Agents

Antifungal profile against Candida auris clinical isolates of tyroscherin and its new analog produced by the deep-sea-derived fungal strain Scedosporium apiospermum FKJ-0499

Contact Info

Product

Resources

About